Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada

References

• Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25–S37. doi:10.1089/dia.2017.0035
   PubMed Web of Science ®Google Scholar
• Parkin CG, Graham C, Smolskis J. Continuous glucose monitoring use in type 1 diabetes: longitudinal analysis demonstrates meaningful improvements in HbA1c and reductions in health care utilization. J Diabetes Sci Technol. 2017;11(3):522–528. doi:10.1177/1932296817693253
   Google Scholar
• McGibbon A, Adams L, Ingersoll K, Kader T, Tugwell B; Diabetes Canada Clinical Practice Guidelines Expert Committee. Glycemic management in adults with type 1 diabetes. Can J Diabetes. 2018;42(Suppl 1):S80–S87. doi:10.1016/j.jcjd.2017.10.012
   Web of Science ®Google Scholar
• Yale JF, Paty B, Senior PA; Diabetes Canada Clinical Practice Guidelines Expert Committee. Hypoglycemia. Can J Diabetes. 2018;42(Suppl 1):S104–S108. doi:10.1016/j.jcjd.2017.10.010
   PubMed Web of Science ®Google Scholar
• Berard LD, Siemens R, Woo V; Diabetes Canada Clinical Practice Guidelines Expert Committee. Monitoring glycemic control. Can J Diabetes. 2018;42(Suppl 1):S47–S53. doi:10.1016/j.jcjd.2017.10.007
   Web of Science ®Google Scholar
• Diabetes Canada. Paying for your glucose monitoring device; November 28, 2019. Available from: https://www.diabetes.ca/managing-my-diabetes/stories/paying-for-glucose-monitoring-devices. Accessed April 28, 2020.
   Google Scholar
• Health Quality Ontario. Continuous monitoring of glucose for type 1 diabetes: a health technology assessment. Ont Health Technol Assess Ser. 2018;18(2):1–160.
   Google Scholar
• Diabetes Canada. Diabetes in Canada Backgrounder. Ottawa: Diabetes Canada; 2020. Available from: https://www.diabetes.ca/DiabetesCanadaWebsite/media/Advocacy-and-Policy/Backgrounder/2020_Backgrounder_Canada_English_FINAL.pdf. Accessed April 22, 2020.
   Google Scholar
• Newswire.ca. Dexcom CGM system now available in Canada; September 09 2019. Available from: https://www.newswire.ca/news-releases/dexcom-g6-r-cgm-system-now-available-in-canada-887735218.html. Accessed April 28, 2020.
   Google Scholar
• Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-world hypoglycemia avoidance with a continuous glucose monitoring system’s predictive low glucose alert. Diabetes Technol Ther. 2019;21(4):155–158. doi:10.1089/dia.2018.0359
   Web of Science ®Google Scholar
• Beck RW, Riddlesworth T, Ruedy K; DIAMOND Study Group. et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371. doi:10.1001/jama.2016.19975.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hessler D, Ruedy KJ, Beck RW; DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40(6):736–774. doi:10.2337/dc17-0133
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26. doi:10.1185/030079904X1980
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27–S40. doi:10.1185/030079904X2006
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714–724. doi:10.1016/j.jval.2014.07.007
   PubMed Web of Science ®Google Scholar
• Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8(4):947–951. doi:10.1007/s13300-017-0281-4
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–1534. doi:10.1185/030079906X115757
   PubMed Web of Science ®Google Scholar
• Matza LS, Stewart KD, Davies EW, Hellmund R, Polonsky WH, Kerr D. Health state utilities associated with glucose monitoring devices. Value Health. 2017;20(3):507–551. doi:10.1016/j.jval.2016.10.007
   Web of Science ®Google Scholar
• Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–470. doi:10.1016/j.jval.2014.03.003
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11(1):90. doi:10.1186/1477-7525-11-90
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Optimal use recommendations forsecond and third-line therapy for patients with type 2 diabetes. Ottawa: The Agency; 2013. (CADTHoptimal use report; vol.3, no. 1d). Available from: https://www.cadth.ca/media/pdf/OP0512_Diabetes_RecsReport_2nd_3rd-line_e.pdf. Accessed April 24, 2020.
   Google Scholar
• Brown ST, Grima DG, Sauriol L. Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus. Clin Ther. 2014;36(11):1576–1578. doi:10.1016/j.clinthera.2014.07.019
   Web of Science ®Google Scholar
• Canadian Institute for Health Information. Patient cost estimator. Ottawa, ON: CIHI; 2020. Available from: https://www.cihi.ca/en/patient-cost-estimator. Accessed April 24, 2020.
   Google Scholar
• Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, Gillett M, Elliot J, Heller S. The Sheffield Type 1 Diabetes Policy Model. HEDS Discussion Paper 13/05. 2013. Available from: https://www.sheffield.ac.uk/scharr/sections/heds/discussion-papers/1305-1.258469. Accessed April 24, 2020.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies 4th edition; March 2017. Available from: https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Accessed April 23, 2020.
   Google Scholar
• Houlden RL, Berard L, Lakoff JM, Woo V, Yale JF; Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes and driving. Can J Diabetes. 2018;42(Suppl 1):S150–S153. doi:10.1016/j.jcjd.2017.10.018
   Web of Science ®Google Scholar
• Miller KM, Beck RW, Bergenstal RM, et al.; T1D Exchange Clinic Network. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36(7):2009–2014. doi:10.2337/dc12-1770
   PubMed Web of Science ®Google Scholar
• O’Reilly DJ, Burke N, Tarride JE, Hahn J, Nurkanovic L. Direct health-care costs and productivity costs associated with hypoglycemia in adults with type 1 and type 2 diabetes mellitus that participated in the Canadian hypoglycemia assessment tool program. Can J Diabetes. 2018;42(6):659–663. doi:10.1016/j.jcjd.2018.01.010
   PubMed Web of Science ®Google Scholar
• Brod M, Wolden M, Christensen T, Bushnell DM. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health. 2013;16(8):1140–1149. doi:10.1016/j.jval.2013.09.002
   PubMed Web of Science ®Google Scholar
• Billings LK, Parkin CG, Price D. Baseline Glycated hemoglobin values predict the magnitude of glycemic improvement in patients with type 1 and type 2 diabetes: subgroup analyses from the DIAMOND study program. Diabetes Technol Ther. 2018;20(8):561‐565. doi:10.1089/dia.2018.0163
   Web of Science ®Google Scholar
• Martyn-Nemeth P, Schwarz Farabi S, Mihailescu D, Nemeth J, Quinn L. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review. J Diabetes Complications. 2016;30(1):167–177. doi:10.1016/j.jdiacomp.2015.09.003
   Web of Science ®Google Scholar
• Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14(5):646. doi:10.3111/13696998.2011.610852
   PubMedGoogle Scholar
• Aronson R, Goldenberg R, Boras D, Skovgaard R, Bajaj H. The Canadian hypoglycemia assessment tool program: insights into rates and implications of hypoglycemia from an observational study. Can J Diabetes. 2018;42(1):11–17. doi:10.1016/j.jcjd.2017.01.007
   PubMed Web of Science ®Google Scholar
• The Nightscout Project. Nightscout #WeAreNotWaiting. 2020. Available from: http://www.nightscout.info/. Accessed April 26, 2020.
   Google Scholar
• Chaugule S, Graham C. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective. J Med Econ. 2017;20(11):1128–1135. doi:10.1080/13696998.2017.1360312
   PubMed Web of Science ®Google Scholar
• Welsh JB, Gao P, Derdzinski M, et al. Accuracy, utilization, and effectiveness comparisons of different continuous glucose monitoring systems. Diabetes Technol Ther. 2019;21(3):128–132. doi:10.1089/dia.2018.0374
   Web of Science ®Google Scholar
• Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21(2):81–85. doi:10.1089/dia.2018.0310
   PubMed Web of Science ®Google Scholar
• Yoo JH, Choi MS, Ahn J, et al. Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther. 2020;22(10):768–776. doi:10.1089/dia.2019.0499.
   PubMed Web of Science ®Google Scholar
• Guo Q, Zang P, Xu S, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabetes Res. 2020;2020:5817074. doi:10.1155/2020/5817074
   PubMed Web of Science ®Google Scholar
• Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care. 2020;43(1):37–43. doi:10.2337/dc19-0888
   PubMed Web of Science ®Google Scholar